- Home
- RYTM
as 09-15-2025 4:00pm EST
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.4B | IPO Year: | 2017 |
| Target Price: | $101.92 | AVG Volume (30 days): | 553.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $45.91 - $106.52 | Next Earning Date: | 11-04-2025 |
| Revenue: | $156,287,000 | Revenue Growth: | 53.55% |
| Revenue Growth (this year): | 44.69% | Revenue Growth (next year): | 63.53% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shulman Joseph | RYTM | Chief Technical Officer | Sep 2 '25 | Sell | $105.30 | 16,781 | $1,767,005.74 | 8,509 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Aug 21 '25 | Sell | $100.07 | 4,188 | $419,090.65 | 8,509 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Aug 13 '25 | Sell | $96.00 | 3,477 | $333,792.00 | 116,915 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Aug 12 '25 | Sell | $96.33 | 24,611 | $2,370,831.77 | 116,915 | |
| German Christopher Paul | RYTM | Corporate Controller & CAO | Aug 12 '25 | Sell | $95.00 | 1,500 | $142,500.00 | 922 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Aug 11 '25 | Sell | $90.08 | 3,984 | $358,891.47 | 8,509 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
FDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM)
MT Newswires
a month ago
Rhythm Pharma's Setmelanotide sNDA for Hypothalamic Obesity Accepted by FDA
GlobeNewswire
a month ago
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
GlobeNewswire
3 months ago
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
Investor's Business Daily
3 months ago
This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues
Insider Monkey
3 months ago
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
Newsfile
4 months ago
Sienna Resources Inc. Announces Private Placement
Energy Global
4 months ago
European Energy completes sale of Polish wind portfolio to Enea Group
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.